International regulators today published a report highlighting their discussions on the effectiveness of existing vaccines against the COVID-19 Omicron variant, regulatory requirements for the variant vaccine, and considerations on clinical study design. The Workshop on the Global Response to the COVID-19 Omicron Variant was organized under the umbrella of the International Coalition of Medicines Regulatory Authorities and took place on 12 January 2022.
Reviewing data on the effects of Omicron, participants concluded that current vaccines offer little protection against this type of infection and mild disease. However, vaccination continues to provide considerable protection against hospitalization and severe COVID-19 with Omicron, especially after a booster dose. It is becoming increasingly clear that booster doses are needed to increase vaccine protection.
Given the potential vaccination approach against Omicron and other virus variants, meeting participants agreed that administration of multiple booster doses at short intervals is not a sustainable approach in the long term. There is a need to develop a long-term strategy on the types of vaccines needed to manage COVID-19 in the future. This is an ongoing global discussion that sits at the intersection of science, public policy and public health and will require coordination among public health decision makers at all levels.
With regard to the updated vaccine structure, global regulators encourage the international scientific community and vaccine developers to look at alternative approaches to univalent vaccines. In the view of regulators, companies should explore the feasibility of developing bivalent or multiagent variant vaccines to determine whether they confer the benefits of univalent vaccines.
Meeting participants also emphasized that clinical studies should be conducted to support the use of the new vaccine. These studies should be designed to demonstrate that the immune response generated by the updated vaccine, measured as neutralizing antibodies, is superior to that obtained from current vaccines. The ability to cross-neutralize other variants of concern by the updated vaccines would be an additional feature in relation to the breadth of protection provided by the updated vaccine.
The meeting built on knowledge and experience gained from previous workshops on COVID-19 vaccine development and virus variants held in 2021, where international regulators emphasized the need for regulatory alignment to accelerate global development and authorization of new or modified COVID-19 vaccines gave against emerging coronavirus variants.
Finally, it is again reminded that;
Most people infected with the virus will experience mild to moderate respiratory illness and recover without the need for special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical conditions such as heart disease, diabetes, chronic respiratory disease or cancer are more likely to develop serious illness. Anyone can become ill with COVID-19 and become seriously ill or die at any age.
The best way to prevent and slow transmission is to be well-informed about the disease and how the virus spreads. Protect yourself and others from infection by staying at least 1 meter away from others, wearing a properly fitted mask, and washing your hands or using alcohol-based rubs. Get vaccinated when it's your turn and follow local guidance.
The virus can be spread in small liquid particles from the mouth or nose of an infected person when an infected person coughs, sneezes, speaks, sings or breathes. These particles range from large respiratory droplets to small aerosols. It is important to practice respiratory etiquette, for example coughing into a bent elbow, and stay home and self-isolate until you feel unwell.
You must be logged in to post a comment.